AI-Driven Mammography Analytics for Enhanced Breast Cancer Detection

AI Driven Mammography Analytics

Client Background


The client is an innovative digital pathology startup focused on AI-powered cancer risk assessment with two commercialized products already transforming patient care. Their goal is to transform breast cancer diagnostics by developing a morphology-driven AI platform that predicts recurrence risk from standard H&E slides, enabling personalized treatment plans. With a team of oncologists and data scientists, they seek a technical partner to build a scalable, FDA-cleared diagnostic tool.

Key objectives:


  • Develop an AI model to analyze H&E slides for early-stage invasive breast cancer recurrence risk
  • Ensure the platform complies with regulatory standards (FDA/CLIA) for clinical use
  • Integrate explainable AI to provide clinicians with interpretable insights


Solution

Gear2

We designed a cloud-based AI diagnostics platform that ingests H&E slides, extracts morphology features, and generates patient-specific risk scores with clinical rationale. The development included:

  • Multi-scanner normalization: Preprocessing pipeline to harmonize slide artifacts (blur, stains, etc.)
  • Hybrid AI architecture: Combines CNNs for feature extraction and graph-based ML for risk modeling
  • Regulatory-ready infrastructure: Audit trails, HIPAA/GDPR compliance, and FDA 21 CFR Part 11 support
  • Clinician UI: Interactive dashboards highlighting high-risk regions and confidence scores

Key Features


The software is now deployed across 20+ labs, with ongoing trials for prostate cancer adaptation. Highlights include:

  • Morphology Feature Engine: Patented algorithm quantifying 500+ tissue biomarkers
  • Dynamic Risk Stratification: Adjusts predictions based on clinical history (e.g., BRCA status)
  • API integrations: Seamless EHR/LIS compatibility (Epic, Cerner, etc.)
  • Real-time QC Flags: Alerts for poor slide quality


Business Value

Icon OptimizationFaster, More Accurate Diagnoses

Reduced pathologist workload by 40% via AI triage of low-risk cases.

Improve

Icon Improving UXRegulatory & Commercial Scalability

Achieved FDA De Novo clearance in 18 months, with modular design for new cancer types.

Boosting revenue

Icon Developing all flowImproved Patient Outcomes

30% increase in early-stage recurrence detection in validation studies.

Competitive edge

Testimonial

Project summary:

Glorium Technologies provided mobile app development services for a healthcare education organization. Their team helped build an application for COVID-19 relief. The solution features simulation training.

Tech Stack:

PythonAWS S3/EC2
HL7/FHIR APIs
Docker
Terraform
GxP validation
React
DICOM viewers
AI
Cloud Analytics

Success Stories

Case studies